Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Study of cannabinoid dependence in animals.

Rafael Maldonado1

  • 1Laboratori de Neurofarmacologia, Facultat de Ciencès de la Salut i de la Vida, Universitat Pompeu Fabra, C/Dr Aiguader 80, 08003 Barcelona, Spain. rafael.maldonado@cexs.upf.es

Pharmacology & Therapeutics
|August 17, 2002
PubMed
Summary

Chronic cannabinoid agonist exposure leads to tolerance and withdrawal symptoms, particularly with agonists like WIN-55,212-2. Antagonist administration precipitates withdrawal, suggesting cannabinoid dependence potential.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gut microbiota as a novel therapeutic target for eating disorders and obesity.

British journal of pharmacology·2026
Same author

In silico prediction of novel effective combinational treatment of chronic pain in individual patients: A joint white paper of the H2020 QSPainRelief consortium.

British journal of pharmacology·2026
Same author

A Male Mouse Model of WIN 55,212-2 Self-Administration to Study Cannabinoid Addiction.

Bio-protocol·2026
Same author

Dysregulated eating behaviour and microbiota-based interventions targeting eating disorders and food addiction.

Gut microbes·2026
Same author

Loss of eating control and cognitive flexibility: Involvement of gut microbiota.

Adicciones·2026
Same author

Targeting dysregulated CB1 receptors in a Down syndrome mouse model improves neurological outcomes.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025

Area of Science:

  • Neuroscience
  • Pharmacology

Background:

  • Cannabinoid agonists are widely studied for their effects and abuse potential.
  • Chronic exposure to cannabinoids often results in tolerance to their pharmacological actions.

Purpose of the Study:

  • To investigate the consequences of chronic cannabinoid agonist exposure, including tolerance, withdrawal, and abuse liability.
  • To explore the role of the CB(1) receptor antagonist SR141716A in cannabinoid withdrawal.

Main Methods:

  • Animal models were used to assess the effects of chronic cannabinoid administration.
  • Drug discrimination, place conditioning, intracranial self-stimulation, and self-administration paradigms were employed.
  • The impact of CB(1) antagonist SR141716A on withdrawal was examined.

Related Experiment Videos

Main Results:

  • Tolerance to cannabinoid effects develops rapidly, likely due to pharmacodynamic changes.
  • Somatic withdrawal signs were observed after chronic WIN-55,212-2, but not THC, though antagonist administration induced withdrawal.
  • Cannabinoids exhibit rewarding properties, influencing the mesolimbic dopaminergic system, with some agonists self-administered by animals.

Conclusions:

  • Cannabinoid agonists can induce tolerance and physical dependence, with varying effects depending on the specific agonist.
  • The CB(1) receptor is implicated in mediating cannabinoid withdrawal.
  • Cannabinoids possess rewarding effects mediated by the mesolimbic dopaminergic system, contributing to their abuse liability.